|
Contrast delivery developer Acist Medical Systems and HealthTrust, a healthcare group purchasing organization, have entered into a three-year contract for the company's cardiovascular injection technology.
CT is being utilized as an adjunctive tool in the evaluation of patients presenting with complicated H1N1 flu cases in hospitals, which can be positive for both the technology and medical imaging agent manufacturers, said life sciences market research group Kalorama Information.
A technique involving the combination of adenosine perfusion CT imaging and cardiac CT angiography adds incremental value in the detection of obstructive coronary artery disease (CAD) for high-risk individuals, according to the results of a study published in the February issue of Radiology.
The FDA’s Division of Drug Marketing, Advertising and Communications has reviewed GE Healthcare’s Web site for its contrast agent, Visipaque (iodixanol) Injection, and deemed the promotional material “misleading because it presents unsubstantiated comparative claims and omits and minimizes the risks associated with Visipaque.”
Coupling an MRI contrast agent, gadolinium, to a nanodiamond complex can increase signal intensity and image contrast, based on a study published online Dec. 28, 2009 in Nano Letters.
Knottin peptides may be a promising platform for designing novel contrast agents for molecular ultrasound imaging of tumor angiogenesis, according to a study presented at the annual Radiological Society of North America (RSNA) meeting.
GE Healthcare has received FDA clearance for its Optima MR450w, a new 70-cm bore, 1.5T MRI system. The larger-bore platform is commonly touted for patients who are obese or claustrophobic.
Acusphere plans to substantially reduce costs while it continues its regulatory discussions with the FDA for its lead product candidate, Imagify (Perflubutane Polymer Microspheres) for injectable suspension, including cutting jobs and consolidating operations.
The FDA's Cardiovascular and Renal Drugs Advisory Committee Wednesday recommended the rejection of the regulatory application of Acusphere's Imagify heart contrast agent, because its benefits do not sufficiently justify the risks associated with the product.
|
Omnipaque (iohexol, GE Healthcare), a low osmolar iodinated contrast agent has the potential to be better tolerated by patients than the more widely used high osmolality iodinated oral contrast agent, meglumine sodium diatrizoate (Gastroview, Mallinckrodt) for CT, according to a study presented Feb.21 at the Abdominal Radiology Course Meeting held by the Society of Gastrointestinal Radiology and the Society of Uroradiology in Orlando.
When added to MRI, gadolinium-based contrast agents were found to substantially enhance the malignancy criteria for primary tumor visualization, as well as increase the accuracy in the detection of lymph node metastases, according to a meta-analysis published in the February edition of the Journal of the National Cancer Institute.
The FDA's Division of Drug Marketing, Advertising and Communications has informed Bracco Diagnostics that its Web site for IsoVue (iopamidol injection) misbrands the drug by omitting and minimizing the risks associated with the agent and contains false and unsubstantiated claims.
Acute adverse reactions from gadolinium-based contrast agents used during MRI to help improve the information seen on the images rarely occur, according to a study published in the February issue of the American Journal of Roentgenology.
Lantheus Medical Imaging touted the benefits of its recently acquired MR angiography (MRA) agent, Ablavar (formerly marketed as Vasovist, gadofosveset trisodium), at the 2009 Radiological Society of North America in Chicago earlier this month.
After years of research regarding gadolinium-based contrast agents used during MRI being linked to the skin disease nephrogenic systemic fibrosis (NSF), the FDA has found the greatest risk in GE Healthcare’s Omniscan, Bayer HealthCare's Magnevist and Covidien’s Optimark.
Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its blood pool MR angiography (MRA) agent, Vasovist, to Lantheus Medical Imaging for aggregate gross cash proceeds of $28 million. In addition, if Epix is unable to exchange all of its $100 million aggregate principal of 3 percent of convertible senior notes, it may be forced to file bankruptcy.
The utilization of contrast echocardiography in technically difficult cases improves endocardial visualization and impacts cardiac diagnosis, resource utilization and patient management, according to a study published online Feb. 11 in the Journal of the American College of Cardiology.
In MR angiography (MRA) of peripheral arteries, injecting contrast medium at a slow, balanced rate can alleviate contamination of veins in the calves while maintaining image quality, according to a multinational team of researchers from China and the United States. Their study, published this month in the American Journal of Roentgenology, suggests that it is possible to increase arterial visibility in the calf while signal-to-noise and contrast-to-noise ratios at higher levels are maintained.
|
RSS 
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).
During the Health IT Standards Committee meeting on Feb. 24 in Washington, D.C., the Clinical Operations Workgroup sought to gather comments on proposed recommendations on implementation specifications for content exchange, vocabulary and code set standards for the Interim Final Rule of meaningful use.
In 2006, the Center for Devices and Radiological Health (CDRH), a branch of the FDA, began examining the number of medical device reports they received. Over the past two years, the number of submitted reports has increased, sparking a demand for the CDRH to make a move to electronic reporting.
A new hospital breaking ground usually isn’t breaking news. But the vision of patient care at one new facility, tentatively named Palomar Medical Center West (PMC West), is currently illegal under California state law.